SCHEMBL4473954

SCHEMBL4473954

Clc1nc(-c2ccccn2)nc2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP1 P53582 5/20 1.00
MAPT P10636 4/20 0.59
ALDH1A1 P00352 2/20 0.59
POLB P06746 1/20 0.59
KMT2A Q03164 6/20 0.57
RAB9A P51151 5/20 0.57
MEN1 O00255 4/20 0.57
NPC1 O15118 3/20 0.57
AGTR1 P30556 1/20 0.57
TDP1 Q9NUW8 4/20 0.57
KDM4E B2RXH2 1/20 0.57
L3MBTL1 Q9Y468 4/20 0.55
LMNA P02545 2/20 0.55
MAPK1 P28482 2/20 0.55
ADORA3 P0DMS8 1/20 0.55
TSHR P16473 1/20 0.55
PPP1CA P62136 2/20 0.54
PDE5A O76074 1/20 0.54
HIF1A Q16665 1/20 0.54
JAK2 O60674 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24138577 0.85 METAP1 (0.73) METAP1MAPTALDH1A1POLBKMT2A
SCHEMBL31169377 0.79 METAP1 (0.66) METAP1MAPTALDH1A1POLBKMT2A
SCHEMBL30394017 0.79 METAP1 (0.66) METAP1MAPTALDH1A1POLBKMT2A
SCHEMBL10705638 0.79 METAP1 (0.66) METAP1MAPTALDH1A1POLBKMT2A
SCHEMBL5738982 0.78 METAP1 (0.63) METAP1MAPTALDH1A1KMT2ARAB9A
SCHEMBL2913642 0.78 METAP1 (0.64) METAP1MAPTALDH1A1POLBKMT2A
SCHEMBL31716509 0.78 METAP1 (0.63) METAP1MAPTALDH1A1POLBKMT2A
SCHEMBL24590229 0.77 METAP1 (0.62) METAP1MAPTALDH1A1POLBKMT2A
SCHEMBL24589753 0.77 METAP1 (0.62) METAP1MAPTALDH1A1POLBKMT2A
SCHEMBL24590225 0.77 METAP1 (0.62) METAP1MAPTALDH1A1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014128206-A1 COMPOUNDS FOR USE IN INHIBITING HIV CAPSID ASSEMBLY Ruprecht-Karls-Universität Heidelberg (DE) 2014-08-28 WO disclosed
EP-2769723-A1 Compounds for use in inhibiting HIV capsid assembly Ruprecht-Karls-Universität Heidelberg (DE) 2014-08-27 EP disclosed
US-8064119-B2 Display element and driving method thereof KONICA MINOLTA HOLDINGS, INC. (JP) 2011-11-22 US disclosed
US-8064119-B2 Display element and driving method thereof KONICA MINOLTA HOLDINGS, INC. (JP) 2011-11-22 US disclosed
US-20110124649-A1 INHIBITORS OF HUMAN METHIONINE AMINOPEPTIDASE 1 AND METHODS OF TREATING DISORDERS THE JOHNS HOPKINS UNIVERSITY (US) 2011-05-26 US disclosed
US-20110124649-A1 INHIBITORS OF HUMAN METHIONINE AMINOPEPTIDASE 1 AND METHODS OF TREATING DISORDERS THE JOHNS HOPKINS UNIVERSITY (US) 2011-05-26 US disclosed
US-20110058244-A1 ELECTROCHROMIC DISPLAY ELEMENT KONICA MINOLTA HOLDINGS, INC. (JP) 2011-03-10 US disclosed
US-20110058244-A1 ELECTROCHROMIC DISPLAY ELEMENT KONICA MINOLTA HOLDINGS, INC. (JP) 2011-03-10 US disclosed
US-20100091352-A1 DISPLAY ELEMENT AND DRIVING METHOD THEREOF KONICA MINOLTA HOLDINGS, INC. (JP) 2010-04-15 US disclosed
US-20100091352-A1 DISPLAY ELEMENT AND DRIVING METHOD THEREOF KONICA MINOLTA HOLDINGS, INC. (JP) 2010-04-15 US disclosed
US-20020025968-A1 Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives OSI PHARMACEUTICALS, INC. 2002-02-28 US disclosed
EP-0579496-B1 4-Aminoquinazoline derivatives, and their use as medicine ONO PHARMACEUTICAL CO (JP) 2001-11-14 EP disclosed
US-5508151-A ENVIRONMENTAL COMPATIBILITY; STABILITY EASTMAN KODAK COMPANY (US) 1996-04-16 US disclosed
US-5439895-A Cardiovascular disorders; inhibitor of thromboxane A2 synthetase and cyclic guanosine 3',5'-monophosphate ONO PHARMACEUTICAL CO., LTD. (JP) 1995-08-08 US disclosed
US-5436233-A Nervous system disorders ONO PHARMACEUTICAL CO., LTD. (JP) 1995-07-25 US disclosed
EP-0579496-A1 4-Aminoquinazoline derivatives, and their use as medicine ONO PHARMACEUTICAL CO., LTD. (JP) 1994-01-19 EP disclosed
EP-0135975-B1 QUINAZOLINE AND ISOQUINOLINE DERIVATIVES AKZO N.V. (NL) 1988-09-14 EP disclosed
US-4694000-A Quinazoline and isoquinoline derivatives AKZO N.V. (NL) 1987-09-15 US disclosed
WO-1985001501-A1 QUINAZOLINE AND ISOQUINOLINE DERIVATIVES AKZO N.V. (NL) 1985-04-11 WO disclosed
EP-0135975-A2 Quinazoline and isoquinoline derivatives AKZO N.V. (NL) 1985-04-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020025968-A1 Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives VHL, MCL1, NFATC1 METAP1 1241/4885MAPT 3912/4885ALDH1A1 1566/4885
US-20110124649-A1 INHIBITORS OF HUMAN METHIONINE AMINOPEPTIDASE 1 AND METHODS OF TREATING DISORDERS METAP1, DNPEP, METAP2 METAP1 1/4885MAPT 1249/4885ALDH1A1 536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.